Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Penelope Anne Mayes"'
Autor:
Angela Luttick, Jennifer E. Fenner, Simon P. Tucker, Jeffrey Peter Mitchell, Chin Yu Lim, Bo Lin, Roland Henry Nearn, Silas Bond, Penelope Anne Mayes, John N. Lambert, Craig J. Morton, Vanessa Anne Sanford, Kelly Helen Anderson, Alistair George Draffan
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 25:976-981
Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, young children and adults. 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones with general structure 1 were previously identified as promising inhibitors
Publikováno v:
Tetrahedron: Asymmetry. 17:3341-3350
Reversing the polarity of the cycloaddition partners in Dane’s steroid synthesis provides ready access to enantiomerically pure, functionally-rich steroidal structures.
Autor:
Filisaty Vounatsos, Andrea J. Robinson, Bradley E. Wilman, Patrick Perlmutter, Penelope Anne Mayes, Gary D. Fallon, Sofia Nordin, Marie-Isabel Aguilar, Mark L Rose
Publikováno v:
Letters in Peptide Science. 10:597-604
Two approaches, based on imino-aldol additions, to the asymmetric synthesis of cyclic β-amino acids are reported. In each case a chiral auxiliary was employed attached either to the enolate or to the imine. The relative efficacy of these two synthet
Publikováno v:
International journal of oncology. 38(5)
Histone deacetylase inhibitors (HDACi) demonstrate considerable in vitro and in vivo activity and clinical efficacy in the treatment of hematological malignancies. Pre-clinical and early phase clinical trials identify therapeutic activity using a com
Publikováno v:
Modern Reduction Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d47e187aa569bcebe38b6ff46b8d3f7
https://doi.org/10.1002/9783527622115.ch4
https://doi.org/10.1002/9783527622115.ch4
Publikováno v:
Monash University
Conformational analogues of the hydroxamic acid Oxamflatin 1—compounds 3a, 3b and 4—have been synthesised to enable evaluation of the impact of varying the linking section on histone deacetylase inhibition. Preliminary testing indicates treatment
Publikováno v:
Blood. 110:4151-4151
Azacitidine (AZA), a demethylating agent, has recently been demonstrated to have efficacy in the treatment of myelodysplasia and acute myeloid leukemia. A potential concern when considering the use of this agent is a recent report demonstrating AZA-m